Volume 3, Issue 12, Page 9 (December 2008)
13 of 31
PREVIEW
FULL TEXT
FULL-TEXT PDF (217 KB)
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
NEED REPRINTS?
BOOKMARK ARTICLE
PHILADELPHIA — Nearly 5 years of treatment with the angiotensin type 1 receptor blocker candesartan did not provide statistical benefit in the prevention of microalbuminuria in patients with diabetes, according to a new post hoc analysis.
PII: S1558-0164(08)70435-8
doi:10.1016/S1558-0164(08)70435-8
© 2008 Elsevier Inc. All rights reserved.
Copyright © 2012 Elsevier Inc. All rights reserved. | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.